Detalhe da pesquisa
1.
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Oncologist
; 24(9): 1149-e807, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31152080